259 Radnor Chester Road
About Mitochon Pharmaceuticals
Mitochon was founded in 2014 with the mission to develop treatments for insidious diseases through the modulation of mitochondrial physiology, with applications to neurodegeneration, neuromuscular, and developmental diseases. Mitochon’s lead programs, MP101 and MP201, specifically harnesses the power of the mitochondria to provide broad neural protection. These compounds elicit mild increases in energy expenditure that result in strengthening cellular survival – similar to the positive effects seen with fasting and exercise. These compounds also induce an important neurotrophin, Brain Derived Neurotrophic Factor (BDNF), involved in cognition and neural growth.
Founder and CEO: Robert Alonso
Founder & CSO: John G. Geisler, PhD
Acting CMO: Robert Elfont MD
Please click here for Mitochon Pharma's job opportunities.
Please click here for Mitochon Pharma's pipeline.
3 articles with Mitochon Pharmaceuticals
This important allowance, along with the Company’s open IND will help secure the path forward for the continued clinical development of MP101 in Huntington’s Disease and it further strengthen Mitochon’s exclusivity for MP-101, a repurposed molecule.
Mitochon Pharmaceuticals Announces First Patent Allowance for Mitochondrial Targeted Therapies for Neurodegeneration
This patent allowance will help secure the path forward for the continued clinical development of MP101 in: Huntington’s Disease, Optic neuritis and Duchenne’s Muscular Dystrophy.
Mitochon Pharma Awarded Grant From The Michael J. Fox Foundation To Support Mitochondrial Research In Parkinson’s